You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫藥業(002422.SZ)2021年淨利潤增長32.94%至11.03億元 擬每10股派4.26元
格隆匯 04-10 16:46

格隆匯4月10日丨科倫藥業(002422.SZ)公佈,2021年度,公司實現營業收入172.77億元,同比增長4.94%;實現毛利96.17億元,增加6.86億元,同比增長7.68%;實現歸屬於上市公司股東的淨利潤11.03億元,增加2.73億元,同比增長32.94%。擬向全體股東每10股派發現金紅利4.26元(含税)。

經營業績變動主要原因是:(1)2021年,儘管局部仍受疫情波動影響,公司全力拓展輸液、非輸液製劑產品市場,營業收入和利潤同比增加;(2)公司近年獲批的仿製藥持續放量,營業收入和利潤增長較快;(3)公司積極優化融資結構,平均融資利率下降,財務費用減少;(4)公司持續大力推進“創新驅動”戰略,研發費用同比增加;(5)子公司川寧生物因當地疫情影響產生停產損失,營業收入及利潤同比下降;(6)公司經營規模擴大,相應的薪酬、折舊及招待費等管理費用增加;(7)子公司博泰生物少數股東持股比例提升,少數股東損失同比大幅增加。

2021年公司33項產品獲批上市,30項產品申報生產,從2017年至2021年12月31日,公司獲批上市94項,有52項處於申報生產階段。公司主要推動12項創新藥物臨牀研究,實行重點項目重點突破。公司堅持准入先行,深度參與國家與地方集採,發揮公司仿製藥序貫上市的產品集羣優勢,使新產品實現快速規模銷售,提升盈利能力。

公司研發創新取得的專利成果保持穩定增長,2021年共申請專利351項,共獲得專利授權195項;截至2021年12月31日,已累計申請國內外專利4,162項,累計獲得專利授權2,258項。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account